

IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS
<p>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed and <i>Haemophilus influenzae</i> Type b (Hib) Conjugate Vaccine (DTaP-Hib)</p> <p>TriHIBit™ [ActHIB® reconstituted with Tripedia®) Sanofi pasteur</p>	<p>Not licensed for use for the first 3 doses</p>	<p>Children needing the fourth dose of DTaP and Hib:</p> <p>Fourth: 0.5 mL IM 6-12 months after the third dose of DTaP and at least 2 months after the last Hib dose and no earlier than 15 months of age</p>	<p>Because of evidence of reduced immunogenicity of the Hib component when used as a combination, TriHIBit is not approved by the Food and Drug Administration for use as the primary series at 2, 4, or 6 months of age. It is approved only for the fourth dose of the DTaP and Hib series. If TriHIBit is administered as one or more doses of the primary series at 2, 4, or 6 months of age, the Hib doses should not be counted, and the child should be revaccinated as age appropriate for Hib. The DTaP doses may be counted as valid and do not need to be repeated.</p> <p>Although TriHIBit cannot be used in the primary series at 2, 4, or 6 months of age, it may be used as the booster (final) dose following a series of single-antigen Hib vaccine or combination hepatitis B–Hib vaccine (Comvax). Therefore, TriHIBit can be used if the child is 12 months of age or younger, has received at least one prior dose of Hib vaccine 2 or more months earlier, and TriHIBit will be the last dose in the Hib series. For example, TriHIBit can be used for the booster dose at 12-15 months of age in a child who has received Comvax or PedvaxHib at 2 and 4 months of age, or three prior doses of HibTiter or ActHib. TriHIBit can also be used at 15-59 months of age in a child who has received at least one prior dose of any Hib-containing vaccine. TriHIBit should not be used if the child has received no prior Hib doses.</p> <p>Adverse Reactions: Refer to Adverse Reaction sections for DTaP and Hib conjugate vaccines.</p> <p>Precautions: See Precaution section for DTaP</p> <p>Contraindications: Hypersensitivity to any vaccine component. See Contraindications sections for DTaP and Hib vaccines</p>